Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in High-Risk, HR+, HER2- Breast Cancer
NCT01674140Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2013
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of everolimus in breast cancer (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Sep 2013; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01674140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674140.